Mora MWL

Language: Spanish
References: 18
Page: 691-697
PDF size: 376.86 Kb.

ABSTRACT

Infection with human papillomavirus is a sexually transmitted infection one of the most common in the world and the main causative agent of cervical cancer, found in 97.9% of cases. HPV affects men and women equally; however, in men it has been associated primarily injuries as anogenital warts and cancers intraepithelial penis and anus. HPV infection in men has been regarded as a minor problem and low relevance. In general it has been dubbed the man as silent vector of this organism, because despite playing a role in the transmission virus, only 1% of them are experiencing clinical signs or symptoms, however, they are possible reservoirs of the virus and transmitting sexually to female population. This article shows statistical data and typification presence of HPV in a male population of reproductive age and clinical validity.

REFERENCES

1. Chul Won Moon. Myofascial Pain Syndrome. J Korean Pain Soc. 2004; 17 (Suppl):S36-S44

2. Davidoff R. Trigger points and myofascial pain: toward understanding how they affect headaches. Cephalalgia. 1998; Vol 18, Issue 7, 436–448.

3. Estévez Rivera E. A. Dolor miofascial. MediUnab. 2001; Vol. 4 Número 12. 161-165.

4. Fenollosa P, de Barutell C et al. Toxina botulínica A (Dysport®) asociada a rehabilitación, en pacientes con dolor miofascial cervical o dorsal primario: un estudio piloto multicéntrico aleatorizado. Rehabilitación. 2011; 45(2):139- 147.

5. Fishbain D et al. Clonazepam Open Clinical Treatment Trial for Myofascial Syndrome Associated Chronic Pain. Pain Medicine. 2000; Vol 1, Issue 4, 332–339.

6. García Franco M, Climent Barbera J, et al. Estudio comparativo de dos técnicas de infiltración miofascial en puntos gatillo: punción seca e inyección de anestésico local. Rehabilitación. 2006; 40(4):188-92.

7. Gerwin R. D. Classification, epidemiology, and natural history of myofascial pain syndrome. Current Pain and Headache Reports. 2001; Vol 5, Issue 5, 412-420.

8. Göbel Hartmut et al. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport®) for the relief of upper back myofascial pain syndrome: Results from a randomized doubleblind placebo-controlled multicentre study. PAIN. 2006; Vol 125, Issue 1; 82-88.

9. González M. J; García M. E. Síndromes de Dolor Miofascial y Fibromialgia. Anestesia en México. 2005; Vol.17, Suplemento 1.

10. Hernández Felix M. F. Síndromes miofasciales. Reumatol Clin. 2009; Vol. 05 Núm.Extra 2. 05:36-9.

11. Insausti J, Djibilian R et al. Técnicas en dolor miofascial. Toxina botulínica. Rev. Soc. Esp. Dolor. 2011; 18(6): 361-365.

12. Insausti Valdivia J. Dolor miofascial, manual de exploración y tratamiento. Ergon, España. 2006.

13. Itza F, Zarza D, et al. Síndrome de dolor miofascial del suelo pélvico: una patóloga urológica muy frecuente. Actas Urol Esp. 2010; 34 (4) : 318–326.

14. Kamanli A. et al. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatology International. October 2005; Vol 25, Issue 8, 604- 611.

15. Lin-Fen Hsieh et al. Efficacy and Side Effects of Diclofenac Patch in Treatment of Patients with Myofascial Pain Syndrome of the Upper Trapezius. Journal of Pain and Symptom Management. 2010; Vol 39, Issue 1, 116-125.

16. Ruiz M et al. Dolor de origen muscular: dolor miofascial y fibromialgia. Rev. Soc. Esp. Dolor. 2007; Vol. 14, n.1 Narón; 36-44.

17. Torres Huerta J, Hernández Santos J et al. Toxina botulínica tipo A para el manejo del dolor en pacientes con síndrome de dolor miofascial crónico. Rev Soc Esp Dolor. 2010;17(1): 22-27.

18. Zuil Escobar J. C, García del Pozo M, González Propin M. Modificaciones del umbral de dolor en un punto gatillo miofascial tras técnica de energía muscular. Rev Soc Esp Dolor. 2010; 17(7):313–319.